ArticleScientific reports2026
Design, synthesis, molecular docking and cytotoxic evaluation of novel pyrimidine-based sulfonamide derivatives as potent anticancer agents: SAR insights and biological profiling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The low selectivity and significant toxicity of current chemotherapeutic medicines make the research and development of novel anticancer agents an urgent necessity. This study used IR, NMR, MS, and elemental studies to rationally design, synthesize, and structurally characterize a novel class of pyrimidine-based sulfonamide derivatives. A wide variety of heterocyclic scaffolds, such as oxadiazoles, thiazolinones, chromenes, pyrazoles, pyrazolopyrimidines, triazolopyrimidines, imidazolidines, and triazines, were made possible by the synthetic approach. HepG2, MCF-7, WI-38, and VERO cell lines were used to test the synthetic compounds’ cytotoxic properties. With IC50 values ranging from 7.4 to 10.2 µg/mL against HepG2 and 8.2 to 10.0 µg/mL against MCF-7, compounds 18, 21, 23, and 24 showed extremely significant anticancer activity, nearly matching the potency of the reference medication 5-fluorouracil. Crucially, these substances showed a good therapeutic index with noticeably reduced toxicity toward normal WI-38 and VERO cells. The most active derivatives’ increased cytotoxicity and selectivity were shown to be largely due to electron-donating groups, balanced lipophilicity, and optimal heterocyclic substitution patterns, according to structure–activity relationship (SAR) research. The experimental results were corroborated by molecular docking experiments against thymidylate synthase (PDB: 2VF5), where compound 23 exhibited the highest binding affinity (S = − 5.5589 kcal/mol), creating strong H-bond interactions with Lys487 and Ala498 within the active region. Overall, compounds 18, 21, 23, and 24 are identified as interesting lead candidates for additional development as effective and selective anticancer medicines based on the combined biology, SAR, and docking results. Future optimization, mechanistic research, and even in vivo assessment can all benefit from these discoveries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.